NLS Pharmaceutics (NASDAQ:NCEL) and Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) Financial Analysis

Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) and NLS Pharmaceutics (NASDAQ:NCEL) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Recordati Industria Chimica E Farmaceutica and NLS Pharmaceutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recordati Industria Chimica E Farmaceutica	$2.96 billion	4.04	$501.92 million	$2.64	21.97
NLS Pharmaceutics	N/A	N/A	-$8.30 million	N/A	N/A

Recordati Industria Chimica E Farmaceutica has higher revenue and earnings than NLS Pharmaceutics.

Risk and Volatility

Recordati Industria Chimica E Farmaceutica has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. Comparatively, NLS Pharmaceutics has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Recordati Industria Chimica E Farmaceutica and NLS Pharmaceutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recordati Industria Chimica E Farmaceutica	0	1	0	2	3.33
NLS Pharmaceutics	1	0	1	0	2.00

NLS Pharmaceutics has a consensus target price of $23.00, suggesting a potential upside of 511.70%. Given NLS Pharmaceutics’ higher possible upside, analysts clearly believe NLS Pharmaceutics is more favorable than Recordati Industria Chimica E Farmaceutica.

Profitability

This table compares Recordati Industria Chimica E Farmaceutica and NLS Pharmaceutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Recordati Industria Chimica E Farmaceutica	17.81%	34.38%	12.70%
NLS Pharmaceutics	N/A	N/A	N/A

Summary

Recordati Industria Chimica E Farmaceutica beats NLS Pharmaceutics on 7 of the 10 factors compared between the two stocks.

About Recordati Industria Chimica E Farmaceutica

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.

About NLS Pharmaceutics

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.